WO2005012543A3 - Método cuantitativo para la detección de yesotoxinas en productos pesqueros basado en la activación que la toxina produce en las fosfodiesterasas celulares y utilidad terapéutica de esta activación. - Google Patents

Método cuantitativo para la detección de yesotoxinas en productos pesqueros basado en la activación que la toxina produce en las fosfodiesterasas celulares y utilidad terapéutica de esta activación. Download PDF

Info

Publication number
WO2005012543A3
WO2005012543A3 PCT/ES2004/000343 ES2004000343W WO2005012543A3 WO 2005012543 A3 WO2005012543 A3 WO 2005012543A3 ES 2004000343 W ES2004000343 W ES 2004000343W WO 2005012543 A3 WO2005012543 A3 WO 2005012543A3
Authority
WO
WIPO (PCT)
Prior art keywords
activation
ytx
pdes
yessotoxins
toxin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/ES2004/000343
Other languages
English (en)
French (fr)
Other versions
WO2005012543A2 (es
Inventor
Lopez Luis Miguel Botana
Rancano Amparo Alfonso
Guldris Maria Jose Pazos
Vieytes Mercedes Rodriguez
Garcia Maria Isabel Loza
Baptista De Sousa Juan Vieites
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Santiago de Compostela
Original Assignee
University of Santiago de Compostela
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US10/566,050 priority Critical patent/US20110065138A1/en
Priority to CA002533600A priority patent/CA2533600A1/en
Priority to JP2006520848A priority patent/JP2006528483A/ja
Priority to DE602004013446T priority patent/DE602004013446D1/de
Priority to AU2004260895A priority patent/AU2004260895A1/en
Priority to EP04742071A priority patent/EP1647599B1/en
Priority to BRPI0412832-0A priority patent/BRPI0412832A/pt
Application filed by University of Santiago de Compostela filed Critical University of Santiago de Compostela
Publication of WO2005012543A2 publication Critical patent/WO2005012543A2/es
Publication of WO2005012543A3 publication Critical patent/WO2005012543A3/es
Anticipated expiration legal-status Critical
Priority to AU2010202232A priority patent/AU2010202232A1/en
Priority to AU2010202237A priority patent/AU2010202237A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Transplantation (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)

Abstract

Método cuantitativo para la detección de yesotoxinas en productos pesqueros basado en la activación que la toxina produce en las fosfodiesterasas celulares y utilidad terapéutica de esta activación. La diana celular de la yesotoxina (YTX) y análogos es la activación de las fosfodiesterasas (PDEs). La unión PDEs-YTX da una señal medible. La union se puede cuantificar mediante un biosensor de afinidad o por fluorescencia. El biosensor detecta interacciones biomoleculares y permite determinar la presencia de YTX por su interacción con las PDEs. Mediante la fluorescencia en placa se determinan las variaciones en la velocidad de degradación del derivado fluorescente antraniloil-AMPc. La velocidad con que las PDEs degradan esta molécula se incrementa en presencia de YTX. La YTX inhibe la activación inmunológica de mastocitos de rata e induce un efecto citotóxico en células de hepatocarcinoma humano lo que implica dos utilidades terapéuticas de las YTXs como compuesto antialérgico y antitumoral.
PCT/ES2004/000343 2003-07-25 2004-07-21 Método cuantitativo para la detección de yesotoxinas en productos pesqueros basado en la activación que la toxina produce en las fosfodiesterasas celulares y utilidad terapéutica de esta activación. Ceased WO2005012543A2 (es)

Priority Applications (9)

Application Number Priority Date Filing Date Title
CA002533600A CA2533600A1 (en) 2003-07-25 2004-07-21 Quantitative method for detecting yessotoxins in fish products based on the activation caused by the toxin in cellular phosphodiesterase and therapeutic usefulness of said activation
JP2006520848A JP2006528483A (ja) 2003-07-25 2004-07-21 細胞ホスホジエステラーゼ中に毒素によって生じる活性化に基づいて魚介類中のｙｅｓｓｏｔｏｘｉｎｓを検出するための定量方法及びこの活性化の治療的な使用
DE602004013446T DE602004013446D1 (de) 2003-07-25 2004-07-21 Quantitatives verfahren zum nachweis von yessotoxinen in fischprodukten auf grundlage der durch das toxin verursachten aktivierung zellulärer phosphodiesterase
AU2004260895A AU2004260895A1 (en) 2003-07-25 2004-07-21 Quantitative method for detecting yessotoxins in fish products based on the activation caused by the toxin in cellular phosphodiesterase and therapeutic usefulness of said activation
EP04742071A EP1647599B1 (en) 2003-07-25 2004-07-21 Quantitative method for detecting yessotoxins in fishery products based on the activation caused by the toxin in cellular phosphodiesterase
US10/566,050 US20110065138A1 (en) 2003-07-25 2004-07-21 Quantitative Method For Detecting Yessotoxins In Fishery Products On Based On The Activation That The Toxin Produces In Cellular Phosphodiesterases And Therapeutic Use Of This Activation
BRPI0412832-0A BRPI0412832A (pt) 2003-07-25 2004-07-21 uso terapêutico das yessotoxinas como inibidores do crescimento de células tumorais humanas
AU2010202237A AU2010202237A1 (en) 2003-07-25 2010-05-31 Therapeutic Use of Yessotoxins as Human Tumor Cell Growth Inhibitors
AU2010202232A AU2010202232A1 (en) 2003-07-25 2010-05-31 Use of Yessotoxins in the Treatment of Allergic and Asthmatic Processes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200301773A ES2235611B2 (es) 2003-07-25 2003-07-25 Metodo cuantitativo para la deteccion de yesotoxinas en productos pesqueros basado en la activacion que producen en las fosfodiesterasas.
ESP200301773 2003-07-25

Publications (2)

Publication Number Publication Date
WO2005012543A2 WO2005012543A2 (es) 2005-02-10
WO2005012543A3 true WO2005012543A3 (es) 2005-03-17

Family

ID=34112518

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/ES2004/000343 Ceased WO2005012543A2 (es) 2003-07-25 2004-07-21 Método cuantitativo para la detección de yesotoxinas en productos pesqueros basado en la activación que la toxina produce en las fosfodiesterasas celulares y utilidad terapéutica de esta activación.

Country Status (12)

Country Link
US (1) US20110065138A1 (es)
EP (3) EP1875907B1 (es)
JP (2) JP2006528483A (es)
CN (1) CN1852988A (es)
AT (3) ATE514423T1 (es)
AU (3) AU2004260895A1 (es)
BR (1) BRPI0412832A (es)
CA (1) CA2533600A1 (es)
DE (1) DE602004013446D1 (es)
ES (4) ES2235611B2 (es)
RU (1) RU2389488C2 (es)
WO (1) WO2005012543A2 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101382531B (zh) * 2008-10-08 2011-12-28 天津商业大学 利用电子鼻检测虾新鲜度的方法
ES2393696B2 (es) * 2012-09-07 2013-06-04 Universidade De Santiago De Compostela Uso de la Yessotoxina y sus derivados para el tratamiento de gliomas
CN105198900A (zh) * 2015-09-22 2015-12-30 国家海洋环境检测中心 虾夷扇贝毒素ytx纯品的提取、制备方法
US10890573B2 (en) 2017-12-19 2021-01-12 International Business Machines Corporation Facile methods to detect toxin in seafood
RU2716233C1 (ru) * 2018-11-13 2020-03-10 Федеральное государственное бюджетное учреждение науки "Федеральный исследовательский центр питания, биотехнологии и безопасности пищи" Способ количественного определения йессотоксинов в моллюсках

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030138853A1 (en) * 2000-08-10 2003-07-24 Joydeep Lahiri Arrays of biological membranes and methods and use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672509A (en) * 1993-08-25 1997-09-30 Pfizer Inc. hPDE IV-C: a human phosphodiesterase IV isozyme
US5858694A (en) * 1997-05-30 1999-01-12 Cell Pathways, Inc. Method for identifying compounds for inhibition of cancerous lesions
AU3635099A (en) * 1997-12-15 1999-07-26 Beth Israel Deaconess Medical Center Methods and reagents for modulating cell motility
RU2136278C1 (ru) * 1998-04-07 1999-09-10 Государственный научный центр вирусологии и биотехнологии "Вектор" Противоопухолевое средство
CN1229339C (zh) * 2000-03-27 2005-11-30 斯克里普斯研究学院 抑制血管生成和肿瘤生长的化合物，含有该化合物的药用制剂，以及该化合物的制药用途
IT1318605B1 (it) * 2000-06-30 2003-08-27 Uni Degli Studi Di Modena E Re Procedimoento per il dosaggio di tossine dsp del gruppo delledinophysitossine e delle yessottossine.
AR033680A1 (es) * 2000-08-30 2004-01-07 Schering Corp Compuestos triciclicos utiles como inhibidores de la farnesil proteino transferasa y su uso para la manufactura de medicamentos como agentes antitumorales
EP1251181A1 (en) * 2001-04-20 2002-10-23 Warner-Lambert Company Non-recombinant cell lines capable of expressing predominantly cyclic nucleotide phosphodiesterase 4 (PDE4) subtype B and their use for the screening of PDE4 subtype-specific modulators

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030138853A1 (en) * 2000-08-10 2003-07-24 Joydeep Lahiri Arrays of biological membranes and methods and use thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ALFONSO, A. ET AL.: "A rapid microplate fluorescence method to detect yessotoxins based on their capacity to activate phosphodiesterases", ANAL. BIOCHEM., vol. 326, no. 1, 1 March 2004 (2004-03-01), pages 93 - 99, XP004488915 *
ALFONSO, A. ET AL.: "Determination of phosphodiesterase activity in rat mast cells using the fluorescent cAMP analogue anthraniloyl cAMP", CELLULAR SIGNALLING, vol. 7, no. 5, 1995, pages 513 - 518, XP002995440 *
ALFONSO, A. ET AL.: "Yessotoxin, a novel phycotoxin, activates phosphodiesterase activity. Effect of yessotoxin on cAMP levels in human lymphocytes", BIOCHEM. PHARMACOL., vol. 65, no. 2, 15 January 2003 (2003-01-15), pages 193 - 208, XP002995441 *
LEIRA, F. ET AL.: "Characterization of distinct apoptotic changes induced by okadaic acid and yessotoxin in the BE(2)-M17 neuroblastoma cell line", TOXICOLOGY IN VITRO, vol. 16, no. 1, February 2002 (2002-02-01), pages 23 - 31, XP002995442 *
RAMSTAD, H. ET AL.: "Repeatability and validity of a fluorimetric HPLC method in the quantification of yessotoxin in blue mussels (Mytilus edulis) related to the mouse bioassay", TOXICON, vol. 39, no. 9, September 2001 (2001-09-01), pages 1393 - 1397, XP002995443 *

Also Published As

Publication number Publication date
EP1875906B1 (en) 2011-06-29
EP1875907A3 (en) 2008-02-27
CN1852988A (zh) 2006-10-25
ATE524174T1 (de) 2011-09-15
JP2006528483A (ja) 2006-12-21
ATE393833T1 (de) 2008-05-15
AU2010202232A1 (en) 2010-07-08
EP1875906A3 (en) 2008-02-27
ES2259894B2 (es) 2008-11-16
ES2235611A1 (es) 2005-07-01
DE602004013446D1 (de) 2008-06-12
EP1875906A2 (en) 2008-01-09
ES2368872T3 (es) 2011-11-23
AU2010202237A1 (en) 2010-06-24
EP1875907A2 (en) 2008-01-09
AU2004260895A1 (en) 2005-02-10
ES2259266B2 (es) 2008-06-01
ES2235611B2 (es) 2006-07-16
US20110065138A1 (en) 2011-03-17
ATE514423T1 (de) 2011-07-15
JP2006325580A (ja) 2006-12-07
EP1647599A2 (en) 2006-04-19
WO2005012543A2 (es) 2005-02-10
EP1875907B1 (en) 2011-09-14
RU2389488C2 (ru) 2010-05-20
CA2533600A1 (en) 2005-02-10
RU2006101631A (ru) 2006-08-27
EP1647599B1 (en) 2008-04-30
BRPI0412832A (pt) 2006-11-21
ES2259266A1 (es) 2006-09-16
ES2259894A1 (es) 2006-10-16

Similar Documents

Publication Publication Date Title
Lee et al. A sensitive method to detect Escherichia coli based on immunomagnetic separation and real-time PCR amplification of aptamers
Li et al. Characterization of ARC-111 as a novel topoisomerase I-targeting anticancer drug
Bashiri et al. Cellular cholesterol accumulation modulates high fat high sucrose (HFHS) diet-induced ER stress and hepatic inflammasome activation in the development of non-alcoholic steatohepatitis
Vettraino et al. Galloflavin suppresses lactate dehydrogenase activity and causes MYC downregulation in Burkitt lymphoma cells through NAD/NADH-dependent inhibition of sirtuin-1
Weisshaar et al. The malate shuttle detoxifies ammonia in exhausted T cells by producing 2-ketoglutarate
Dos Anjos et al. Detection of harmful cyanobacteria and their toxins by both PCR amplification and LC-MS during a bloom event
WO2005117952A3 (en) Treatment methods utilizing albumin-binding proteins as targets
JP2009536834A5 (es)
WO2006108075A3 (en) Compositions and methods for enhancing drug sensitivity and treating drug resistant infections an diseases
MX2009008486A (es) Imidazoquinolinas como inhibidores dobles de cinasa de lipido y mtor.
Fiehn et al. Targeted drug delivery by in vivo coupling to endogenous albumin: an albumin-binding prodrug of methotrexate (MTX) is better than MTX in the treatment of murine collagen-induced arthritis
TNSN08511A1 (en) Lyophilized formulations of anti-egfr antibodies
MA29032B1 (fr) Produits composes contenant des epothilones et des inhibiteurs des proteines tyrosine kinases, et leurs utilisations pharmaceutiques
EA200970062A1 (ru) Определение подлинности потребляемых продуктов с использованием сахаридов в качестве маркеров
WO2008027162A3 (en) 129xe biosensors and their use
WO2006083305A8 (en) Methods and compositions for the detection of biological molecules using a two particle complex
MY157955A (en) Detection of a target antigen irrespective of the presence or absence of a corresponding therapeutic antibody
WO2006002243A3 (en) Methods of oligosaccharide profiling for the detection of cancer
WO2003100000A3 (en) Amplification and overexpression of oncogenes
Sharma et al. Insulin resistance corresponds with a progressive increase in NOD1 in high fat diet-fed mice
WO2006102574A3 (en) Detection of gdf-8 modulating agents
ATE426675T1 (de) Differenzialdiagnostik mit hepcidin
WO2007067983A3 (en) Sulfotyrosine specific antibodies and uses therefor
WO2007047924A3 (en) Improved target ligand detection
Jotwani et al. Nuclear factor‐κB p50 subunits in chronic periodontitis and Porphyromonas gingivalis lipopolysaccharide‐pulsed dendritic cells

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200480021338.X

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004742071

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 544838

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2533600

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006520848

Country of ref document: JP

Ref document number: 2004260895

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/001029

Country of ref document: MX

Ref document number: PA/a/2006/001030

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2006/01141

Country of ref document: ZA

Ref document number: 200601141

Country of ref document: ZA

ENP Entry into the national phase

Ref document number: 2004260895

Country of ref document: AU

Date of ref document: 20040721

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004260895

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006101631

Country of ref document: RU

WWP Wipo information: published in national office

Ref document number: 2004742071

Country of ref document: EP

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
ENP Entry into the national phase

Ref document number: PI0412832

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 10566050

Country of ref document: US

WWG Wipo information: grant in national office

Ref document number: 2004742071

Country of ref document: EP